470 related articles for article (PubMed ID: 32360434)
1. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
[TBL] [Abstract][Full Text] [Related]
2. Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z; Aristu-Zabalza P; Andrés-Rozas M; Robert C; Ortega-Ribera M; Fernández-Iglesias A; Broqua P; Junien JL; Wettstein G; Bosch J; Gracia-Sancho J
J Hepatol; 2021 May; 74(5):1188-1199. PubMed ID: 33278455
[TBL] [Abstract][Full Text] [Related]
3. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
4. Regulation of the macrophage-hepatic stellate cell interaction by targeting macrophage peroxisome proliferator-activated receptor gamma to prevent non-alcoholic steatohepatitis progression in mice.
Ni XX; Ji PX; Chen YX; Li XY; Sheng L; Lian M; Guo CJ; Hua J
Liver Int; 2022 Dec; 42(12):2696-2712. PubMed ID: 36165186
[TBL] [Abstract][Full Text] [Related]
5. PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.
Rogue A; Anthérieu S; Vluggens A; Umbdenstock T; Claude N; de la Moureyre-Spire C; Weaver RJ; Guillouzo A
Toxicol Appl Pharmacol; 2014 Apr; 276(1):73-81. PubMed ID: 24534255
[TBL] [Abstract][Full Text] [Related]
6. Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver.
Zhu YX; Zhang ML; Zhong Y; Wang C; Jia WP
J Diabetes Res; 2016; 2016():8315454. PubMed ID: 26770990
[TBL] [Abstract][Full Text] [Related]
7. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
8. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
[TBL] [Abstract][Full Text] [Related]
9. Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
Boeckmans J; Natale A; Rombaut M; Buyl K; Rogiers V; De Kock J; Vanhaecke T; M Rodrigues R
Cells; 2019 Dec; 9(1):. PubMed ID: 31877771
[TBL] [Abstract][Full Text] [Related]
10. Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.
Shiri-Sverdlov R; Wouters K; van Gorp PJ; Gijbels MJ; Noel B; Buffat L; Staels B; Maeda N; van Bilsen M; Hofker MH
J Hepatol; 2006 Apr; 44(4):732-41. PubMed ID: 16466828
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM; Bedossa P; Ratziu V; Anstee QM; Bugianesi E; Sanyal AJ; Loomba R; Harrison SA; Balabanska R; Mateva L; Lanthier N; Alkhouri N; Moreno C; Schattenberg JM; Stefanova-Petrova D; Vonghia L; Rouzier R; Guillaume M; Hodge A; Romero-Gómez M; Huot-Marchand P; Baudin M; Richard MP; Abitbol JL; Broqua P; Junien JL; Abdelmalek MF;
N Engl J Med; 2021 Oct; 385(17):1547-1558. PubMed ID: 34670042
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect.
Yan F; Wang Q; Xu C; Cao M; Zhou X; Wang T; Yu C; Jing F; Chen W; Gao L; Zhao J
PLoS One; 2014; 9(6):e99245. PubMed ID: 24926685
[TBL] [Abstract][Full Text] [Related]
13. Regulation of lipid-induced macrophage polarization through modulating peroxisome proliferator-activated receptor-gamma activity affects hepatic lipid metabolism via a Toll-like receptor 4/NF-κB signaling pathway.
Wu HM; Ni XX; Xu QY; Wang Q; Li XY; Hua J
J Gastroenterol Hepatol; 2020 Nov; 35(11):1998-2008. PubMed ID: 32128893
[TBL] [Abstract][Full Text] [Related]
14. New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease.
Sahebkar A; Chew GT; Watts GF
Expert Opin Pharmacother; 2014 Mar; 15(4):493-503. PubMed ID: 24428677
[TBL] [Abstract][Full Text] [Related]
15. Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Staels B; Rubenstrunk A; Noel B; Rigou G; Delataille P; Millatt LJ; Baron M; Lucas A; Tailleux A; Hum DW; Ratziu V; Cariou B; Hanf R
Hepatology; 2013 Dec; 58(6):1941-52. PubMed ID: 23703580
[TBL] [Abstract][Full Text] [Related]
16. Cell-specific PPARγ deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells.
Morán-Salvador E; Titos E; Rius B; González-Périz A; García-Alonso V; López-Vicario C; Miquel R; Barak Y; Arroyo V; Clària J
J Hepatol; 2013 Nov; 59(5):1045-53. PubMed ID: 23831119
[TBL] [Abstract][Full Text] [Related]
17. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis.
Wettstein G; Luccarini JM; Poekes L; Faye P; Kupkowski F; Adarbes V; Defrêne E; Estivalet C; Gawronski X; Jantzen I; Philippot A; Tessier J; Tuyaa-Boustugue P; Oakley F; Mann DA; Leclercq I; Francque S; Konstantinova I; Broqua P; Junien JL
Hepatol Commun; 2017 Aug; 1(6):524-537. PubMed ID: 29404476
[TBL] [Abstract][Full Text] [Related]
18. The protective effects of the β3 adrenergic receptor agonist BRL37344 against liver steatosis and inflammation in a rat model of high-fat diet-induced nonalcoholic fatty liver disease (NAFLD).
Wang Z; Li S; Wang R; Guo L; Xu D; Zhang T; Xu Y; Wang W; Wang M; Gan Z; Wang X
Mol Med; 2020 Jun; 26(1):54. PubMed ID: 32503411
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review.
Tidwell J; Balassiano N; Shaikh A; Nassar M
World J Hepatol; 2023 Aug; 15(8):1001-1012. PubMed ID: 37701920
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of the chemokine CCL2 (MCP-1) diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.
Baeck C; Wehr A; Karlmark KR; Heymann F; Vucur M; Gassler N; Huss S; Klussmann S; Eulberg D; Luedde T; Trautwein C; Tacke F
Gut; 2012 Mar; 61(3):416-26. PubMed ID: 21813474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
